By Chris Wack

 

Y-mAbs Therapeutics Inc. said Tuesday that the biologics license application for Omblastys (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration.

The FDA set an action date of Nov. 30, 2022, under the Prescription Drug User Fee Act, and indicated it is planning to hold an advisory committee meeting in October 2022 to discuss the application, Y-mAbs said.

Omblastys has a rare pediatric disease designation which, if approved, will provide Y-mAbs with a priority review voucher.

Researchers at Memorial Sloan Kettering Cancer Center developed omburtamab, which is exclusively licensed by MSK to Y-mAbs. As a result of the licensing arrangement, MSK has institutional financial interests in the compound and in Y-mAbs.

Y-mAbs shares rose 7% to $12.50 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 31, 2022 09:39 ET (13:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Y mAbs Therapeutics Charts.
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Y mAbs Therapeutics Charts.